Sermorelin and Tesamorelin are both growth hormone-releasing hormone (GHRH) analogs, functioning as growth hormone secretagogues. Sermorelin is being explored for various applications including age-related sleep disturbances, abdominal fat reduction in obesity, and as a diagnostic tool for adult growth hormone deficiency. Tesamorelin, on the other hand, has a more focused body of evidence in our corpus, primarily demonstrating efficacy in reducing visceral adipose tissue (VAT) in individuals with HIV-associated lipodystrophy, and is also being investigated for its potential in reducing liver fat in MASLD and improving brain function in HIV patients with abdominal obesity.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Drug class | ghrh analog | ghrh analog |
| Studies in corpus | 89 | 36 |
| Highest evidence tier | rct | meta analysis |
| Evidence tier mix | other · 26 rct · 15 cohort · 1 in vitro · 19 preclinical animal · 22 review · 2 | case report · 1 other · 11 cohort · 2 rct · 12 preclinical animal · 2 review · 3 meta analysis · 1 in vitro · 2 |
| Studies with explicit sample size | 2 | 1 |
| Head-to-head studies in corpus | 15 | |
Studies in our corpus that mention both Sermorelin and Tesamorelin — the gold-standard direct comparison evidence.
This research highlights tesamorelin's potential as a targeted therapeutic option for managing HIV lipodystrophy, offering more than just cosmetic benefits. The significant reduction in visceral fat, coupled with improved lipid profiles, suggests a direct i…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of its pharmacokinetic and pharmacodynamic…
These findings suggest that GHRH therapy could represent a novel therapeutic strategy for improving cardiac function and quality of life in older adults with congestive heart failure and reduced growth hormone effect. The observed improvements in LVEF and c…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing visceral adipose tissue (VAT) can alleviat…
This study provides compelling evidence that tesamorelin could be a highly effective pharmacological intervention for MASLD, addressing a critical unmet medical need. The significant reduction in liver fat observed suggests a strong potential to halt or eve…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and physical decline in a population disproporti…
This highly sensitive and robust nano LC-Q/Orbitrap MS method represents a significant advancement in the detection of GHRH and its analogs, which are frequently abused performance-enhancing drugs. The enhanced sensitivity and specificity will greatly impro…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown metabolites, it provides WADA-accredited l…
The intent behind this withdrawn study highlights a critical unmet need: finding effective treatments for sleep-disordered breathing in patients with lipodystrophy. If Tesamorelin could demonstrably improve sleep apnea in this vulnerable population, it woul…
This study, had it been completed, could have provided crucial evidence for a novel therapeutic strategy to mitigate cardiovascular risk in individuals with abdominal obesity. By demonstrating a direct link between GHRH analogue-induced VAT reduction and de…
Direct head-to-head trials comparing Sermorelin and Tesamorelin are present in our corpus, with 15 such studies. Tesamorelin's research in our corpus is heavily concentrated on HIV-associated lipodystrophy, where it has shown sustained efficacy and long-term safety in reducing visceral fat and improving body composition. It has also demonstrated potential in reducing liver fat in MASLD and improving brain function in HIV patients. Sermorelin, based on the studies indexed here, is being investigated for broader applications, including improving sleep quality and reducing abdominal fat in obesity, as well as its utility in diagnosing growth hormone deficiency. Both peptides are subject to detection in anti-doping contexts, with advanced analytical methods being developed for their identification. While both are GHRH analogs, the specific therapeutic areas where their efficacy is most supported by the indexed studies appear to diverge, with Tesamorelin having stronger evidence for its role in metabolic complications associated with HIV.
Looking for vendor-level purity, endotoxin, and HPLC data on Sermorelin or Tesamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.